Premium
Aminoglutethimide‐induced bone marrow injury. Report of a case and review of the literature
Author(s) -
Young James A.,
Newcomer Lee N.,
Keller Alan M.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19841015)54:8<1731::aid-cncr2820540842>3.0.co;2-f
Subject(s) - aminoglutethimide , medicine , pancytopenia , leukopenia , clinical trial , breast cancer , clinical research , incidence (geometry) , cancer , bone marrow , oncology , surgery , chemotherapy , physics , aromatase , optics
A patient with advanced breast cancer who died of septicemia associated with aminoglutethimide induced agranulcytosis, is reported. Aminoglutethimide is effective and widely used in the treatment of metastatic adenocarcinoma of breast. Thrombocytopenia, leukopenia, or pancytopenia have been reported as complications of therapy in 1.6% of 1345 patients treated in recently published clinical trials employing aminoglutethimide; and this may underestimate the true incidence of this drug side effect. Implications for clinical research and clinical practice are discussed.